Business News • PR NewsWire • Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

PLYMOUTH MEETING, Pa., Nov. 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer,...

View More : http://www.prnewswire.com/news-releases/inovio-pharmaceuticals-to-independently-develop-prostate-cancer-immunotherapy-wi...

Releted News by prnewswire

Influential Speakers to Share Insights at NextGen Auto International Summit China 2014

Apple iPhone 6 - The New Campus Card?

Good to the Last Bite: Airbnb Unveils Pineapple Magazine

Inovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio's Hepatitis B Immunotherapy

Application Performance Management Evolves Rapidly to Keep Pace with Changing IT Architectures in Asia-Pacific: Frost & Sullivan

IAPAC, defensores de direitos dos portadores de HIV e AbbVie apresentam ferramentas antes do Dia Mundial da AIDS para fortalecer o diálogo entre as mulheres que vivem com HIV e seus provedores de serviços de saúde